Producer
Centrient Pharmaceuticals B.V.
Dutch pharmaceutical API company (HQ Rotterdam; private; formerly DSM Sinochem Pharmaceuticals — a JV between DSM N.V. Netherlands and Sinochem Group China, formed 2011; sold to Bain Capital in 2018 and renamed Centrient Pharmaceuticals); produces 6-APA, 7-ADCA (cephalosporin nucleus), and other beta-lactam antibiotic APIs at manufacturing plants in China (Jiangxi and Hebei) and the Netherlands (Delft). Centrient is the world's 2nd or 3rd-largest 6-APA producer. The company's ownership history reflects the globalization of antibiotic manufacturing: Dutch chemicals heritage (DSM), Chinese state enterprise partnership (Sinochem), and private equity management (Bain Capital). Centrient markets its APIs for amoxicillin, ampicillin, and other penicillins to generic pharmaceutical companies worldwide.
2
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
2 inputs Centrient Pharmaceuticals B.V. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Centrient Pharmaceuticals B.V. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Penicillin Nuclei (6-APA)
50%Cephalosporin Nuclei (7-ADCA/7-ACA)
35%Specialty Antibiotic APIs
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2024
Centrient Pharmaceuticals' ownership chain is a compressed history of pharmaceutical supply chain globalization: Dutch chemical company (DSM) pioneered enzymatic antibiotic manufacturing → DSM joint-ventured with Chinese state enterprise (Sinochem) to access cheaper Chinese manufacturing → Bain Capital private equity acquired the JV → production primarily occurs at Chinese facilities, management in Rotterdam. Most of the world's amoxicillin and cephalosporin supply chain for Western markets flows through this structure: Dutch/Western IP, Chinese manufacturing, PE financial management. The global antibiotic supply chain for WHO essential medicines thus depends on a private equity portfolio company with Chinese manufacturing and Dutch regulatory positioning. Centrient's Delft (Netherlands) facility and Jiangxi/Hebei (China) facilities together represent the most significant non-Indian beta-lactam API production base outside China.
Centrient Pharmaceuticals B.V. ↗Origin2023
Centrient Pharmaceuticals' manufacturing heritage originates from DSM (Royal DSM, Netherlands) — specifically from DSM's 1990s breakthrough in enzymatic penicillin splitting. The traditional chemical method for producing 6-APA (splitting penicillin G) used hazardous solvents and low temperatures (-40°C); DSM's process engineers developed immobilized penicillin acylase (an enzyme) that cleaves penicillin G to 6-APA in water at room temperature — dramatically reducing waste solvents, energy consumption, and production cost. This "green chemistry" enzymatic splitting became the global standard; Chinese producers later licensed or independently developed similar enzymatic processes. DSM spun the antibiotics business into a joint venture with China's Sinochem in 2011 (DSM Sinochem Pharmaceuticals), then Bain Capital acquired and renamed it Centrient in 2018. The Dutch enzymatic biotech that invented cleaner penicillin synthesis is now a Bain Capital PE portfolio company with most production in China.
Centrient Pharmaceuticals B.V. ↗